Vaccine Contract Manufacturing Market Size To Surpass USD 8.92 Bn By 2032

The global vaccine contract manufacturing market size was valued at USD 3.1 billion in 2022 and is projected to surpass around USD 8.92 billion by 2032, expanding at a remarkable CAGR of 11.2% from 2023 to 2032.

The global vaccine contract manufacturing market size is expected to reach around USD 6.44 billion by 2029. North America has held the maximum market share of 42% in 2022.

The vaccine contract manufacturing sector is an extra step in the vaccine lifecycle wherein the processes specific to vaccine manufacturing are outsourced to an external organization called a contract manufacturing organization. Abbreviated as CMO, the contract manufacturing organizations are primarily responsible for the large-scale production of the developed vaccine; however, they may also provide secondary services like pre-formulation and formulation-related procedures, protocol designing, non-clinical studies, pre-clinical preparations, registration batches, etc. These entities possess the prerequisite expertise, infrastructure, and dedicated facilities to aid the production of the necessary quantity of products on behalf of the developers.
 

Download the Sample Copy@ https://www.precedenceresearch.com/sample/3421

The outsourcing of vaccine manufacturing-related functions has been escalating globally due to a reduction in developmental costs and stringent production protocols. Based on the type of vaccine, inactivated and live attenuated vaccine manufacturing in terms of growth and size. Owing to a well-established history and known accomplishments, the inactivated vaccines segment has witnessed significant growth. This preferred vaccine option led to a demand for developers to contract services of specialized manufacturing entities. CMOs with the technical knowledge required to handle attenuated vaccines are also in high demand due to the risks associated with handling a live, potentially deadly micro-organism and requiring relevant expertise and specialized facilities for safe and effective production.

In terms of stages, the upstream processes show greater expansion as they provide services crucial for the overall manufacturing process. These included operations like cell culture maintenance, fermentation, and vaccine development and are resource-intensive activities requiring technical know-how. On the other hand, downstream processes involve but are not limited to product formulation, packaging, and distribution. These processes contribute towards the safety, efficacy, and accessibility of the vaccine and need specialized equipment, expertise, and specialized regulatory guidance. Developers prefer to outsource these downstream tasks to regulate operations, minimize costs, and expedite production.

Key Insights:

• In 2022, the attenuated vaccines segment accounted for the highest revenue share of 28%.
• Over the forecast period, the inactivated vaccinations segment is expected to grow at an impressive CAGR of 12.7%.
• In 2022, the downstream segment contributed about 68% of total revenue share.
• Over the projected period, the upstream segment is expected to increase at the quickest CAGR.
• In 2022, the human-use segment had the largest revenue share of 69%.
• Over the anticipated period, the veterinary segment is expected to rise at a notable CAGR of 13.3%.

Growth Factors:

• The vaccine contract manufacturing market has witnessed substantial inflation owing to the recent pandemic. An urgent requirement for large-scale production of vaccines led to increased demand for the services of contract manufacturing organizations, specifically for those with expertise in mRNA and viral vector-based vaccines. Add to this regulator relaxations and accelerated investments, and manufacturing companies experienced a period of favorable conditions to adapt and cost-effectively upscale their services. The persisting fear post-Covid and growing awareness about emerging diseases drive the growth of vaccine development, which in turn promotes the vaccine contract manufacturing market.  
• Vaccination development and its contract manufacturing market represent some lucrative business opportunities. CMOs exploit the global expanding demand for vaccines by providing flexible and scalable manufacturing services. Furthermore, the key players of the market heavily invest in novel manufacturing technologies and modern infrastructure to gain dominance by keeping up with the ongoing trends in the healthcare sector. Strategic collaborations with vaccine-developing entities ensure stable maintenance and potential growth opportunities.
• Vaccination campaigns and state initiatives play a crucial role in the fight against infectious disease, ensuring public well-being. Public vaccination drives exhibited over a couple of decades were a major factor contributing towards the maintenance of the stable market over time. Diseases like influenza and polio and related federal initiatives ensure a continuous demand for the services of CMOs.

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308

Regional Stance

North America accounted for the biggest revenue share of 42% in 2022. For a number of reasons, North America dominates the market for contract manufacture of vaccines. It gains from an established biotechnology and pharmaceutical sector, where a huge population and a strong emphasis on healthcare create a significant demand for vaccinations. The area is a desirable location for contract manufacturing organisations (CMOs) due to its advanced manufacturing infrastructure, established regulatory frameworks, and qualified workforce.

North America's leading position in the market is further cemented by the presence of major vaccine developers and government measures to support vaccine manufacture, establishing the region as a vital contributor to the industry's growth.

Asia-Pacific is predicted to experience the fastest rate of growth. Due to a number of important factors, the vaccine contract manufacturing market is expected to grow significantly in the Asia-Pacific region. First of all, there is a greater need for vaccines due to its sizable and expanding population. Second, the strong pharmaceutical and biotechnology sectors in Asia-Pacific draw international vaccine developers looking for low-cost manufacturing options. The area also gains from having a highly skilled labour population and modern manufacturing capabilities. Furthermore, it is a desirable location for vaccine contract manufacturing due to its favourable regulatory conditions and less labour costs. Asia-Pacific hence continues to play a significant role in the expansion of the global vaccine contract manufacturing market.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/3421

Vaccine Contract Manufacturing Market Scope

Market Potential

Veterinary applications are gradually emerging as a significant shareholder in the vaccine market. An escalating amount of focus on animal cruelty and overall wellbeing has resulted in substantial development in this field. With a special emphasis on health and disease, the veterinary segment has started to gain momentum in the vaccination development and manufacturing market. A general knowledge and recognition of animal infecting diseases and the possibility of transmission between species highlights the significance of vaccines in this sector. Moreover, a lot faster and less complex regulatory processes compared to those of human-use vaccines made veterinary applications of vaccines a profitable avenue for contract manufacturing organizations.

Growing awareness about previously neglected diseases following the aftermaths of the pandemic created vast potential for the growth of the vaccine contract manufacturing market. Combined with the continuous development of technologies involved in R&D, the growing prevalence of diseases, and preventative strategy designing, this industry has a huge scope. A large number of initiatives favoring vaccinations, infrastructural and operational benefits, and growing patient demographics, especially newborns and minors, are actively promoting the growth of the market.

In terms of upcoming technologies, cell and gene therapy alternatives show substantial potential in the market. Capable of addressing the unmet therapeutic needs associated with difficult disorders, these options emerge as a promising avenue. Pharmaceutical companies are slowly shifting their focus toward the development and commercialization of these therapies. This, in turn, has created a major demand for cell and gene therapy development and manufacturing organizations. 

Industry Spotlight:

• In October 2023, Lonza and Vaxcyte decided to expand their collaboration for the global commercial manufacturing of broad-spectrum pneumococcal conjugate vaccines. The two companies originally entered a partnership in June of the same year to support the scale-up and commercialization of the cell therapy portfolio of Vertex T1D. Under the conditions stipulated in the agreement, Lonza will facilitate the production of Vaxcyte's key components, including necessary biochemical compounds. The custom-built Lonza's Ibex® Dedicate Biopark will be a part of its manufacturing suite.   
• In June 2023, Lonza acquired Synaffix BV. Focused on enhancing the company's bioconjugate potential via the integration of Synaffix's technologies. The acquisition further strengthened their dedication to the development of bioconjugate technology.  
• In April 2023, FUJIFILM Diosynth Biotechnologies decided to acquire 41 acres of land in North Carolina. The piece of land posed a strategic benefit to the company as it was located adjacent to its existing RTP campus. This acquisition aims to enhance the production capacity for biologics.  
• In July 2023, Merck unveiled plans to expand its laboratory space and production capabilities in Lenexa, Kansas, USA. This expansion aimed to enhance its capacity for manufacturing cell culture media and accelerate the production of innovative dry powder media, crucial for processes like vaccine manufacturing and gene therapy.

Related Reports:

• Healthcare Contract Manufacturing Market: The global healthcare contract manufacturing market size is projected to be worth around USD 563.3 billion by 2032 from USD 236.9 billion in 2022 and is expanding at a CAGR of 9.1% during the forecast period 2023 to 2032.
   
• Pharmaceutical Contract Manufacturing and Research Services Market: The global pharmaceutical contract manufacturing and research services market size is anticipated to reach around USD 435.53 billion by 2032 from USD 216.3 billion in 2022 and is poised to grow at a CAGR of 7.3% during the forecast period from 2023 to 2032.
   
• Nutraceutical Contract Manufacturing Services Market: The global nutraceutical contract manufacturing services market size is expected to hit around USD 329.12 billion by 2032 from USD 147.6 billion in 2022 and is poised to grow at a CAGR of 8.4% during the forecast period from 2023 to 2032.

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308

Market Key Players:

• Lonza
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Ajinomoto Althea, Inc.
• Merck KgaA
• Cytovance Biologics
• Catalent, Inc.
• IDT Biologika GmbH
• Albany Molecular Research, Inc.
• PRA Health Sciences
• ICON plc.
• Pharmaceutical Product Development, LLC
• Cobra Bio
• Paragon Bioservices, Inc.

Company Synopsis

Lonza

Founded in 1897, Lonza is a widely preferred partner for pharmaceutical, biotech, and nutrition companies globally. The Swiss Alps-based company focuses on aiding procedures that help prevent illness while supporting a healthier lifestyle. Lonza optimizes its scientific innovation and manufacturing technologies to provide its clients with tools to serve their patients and consumers. The group caters to a wide range of services and products for their clients. These range from initial phase development to custom designing and manufacturing of active products to innovative forms of drug dosage or regimes. The company boasts a workforce of more than 17,500 full-time employees contributing to high-performing teams as well as individual positions that make a significant impact on businesses and communities. In the financial year of 2022, Lonza generated 6.2 billion Swiss Franc in sales with a CORE EBITDA of 2 billion Swiss Franc.

The 2023 half-yearly financial document reported CHF 3.1 billion in sales and CORE EBITDA of CHF 922 million; this accounts for 5.6% growth in sales and a profitability margin of 30%. The company maintains a secondary listing on the SGX Singapore Exchange and also has its shares listed on the SIX Swiss Exchange and Swiss Market Index. 

Ajinomoto Althea, Inc.

Ajinomoto Bio-Pharma Services is a member of the Ajinomoto Group companies focused on the development, research, and manufacture of products for industries such as pharmaceuticals, chemicals, sports nutrition, nutraceuticals, food seasonings, consumer food products, beauty, etc. Established originally in the 1770s for the manufacture of black powder, the group uses its innovation, accountability, teamwork, and communication to provide trusted partnerships, responsive service, and peace of mind to our customers.

With operations globally spread across 35 countries and regions and with more than 100 manufacturing sites and supporting offices, Ajinomoto Bio-Pharma Services has emerged as a major key player. The Tokyo-headquartered group received the CMO Leadership Awards for the two successive financial years of 2022 and 2023. Ajinomoto Bio-Pharma Services has recently also received FDA's approval for a high potency fill line.

Market Segmentation

By Vaccine Type

• Attenuated
• Inactivated
• Subunit-based
• Toxoid-based
• DNA-based
   

By Workflow

• Downstream
• Upstream
   

By Application

• Human Use
• Veterinary
   

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Browse Table of Contents: https://www.precedenceresearch.com/table-of-content/3421

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/3421

Unlocking Market Insights through Data Excellence 

The "Precedence Statistics" flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today's dynamic and data-driven world. 

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Web: https://www.precedenceresearch.com/

Our Blogs:

https://www.towardshealthcare.com

https://www.towardspackaging.com

For Latest Update Follow Us:

Linkedin | Facebook | Twitter